LUNG CANCER

Register Now

Interpretation & Reporting

IHC and special stains

+A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib

A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib

Thorne-Nuzzo T, et al.

A study on the automated ALK (D5F3) companion diagnostic IHC assay available from Ventana and its correlation with outcomes for patients with ALK-rearranged lung cancers
Register now to review full resource. Or, if you have registered, login now.

+GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung.

GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung.

Berg, Kyra B. MD; Churg, Andrew MD

The authors suggest using GATA3 immunostain as a marker to distingush between sarcomatoid lung carcinomas and sarcomatoid mesotheliomas. This stain shows a diffuse positivity with the latter but is mostly negative in sarcomatoid lung carcinomas.
Register now to review full resource. Or, if you have registered, login now.

+EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer

EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer

Sakakibara R, Inamura K, Tambo Y, et al.

This article reviews the validity of PD-L1 expression testing in EBUS obtained cytology samples using the EPR116 Abcam antibody. The authors found superior yields with EBUS vs transbronchial biopsies and good concordnace between EBUS specimen and primary tumor for PD-L1 expression.
Register now to review full resource. Or, if you have registered, login now.

+Improving Selection Criteria for ALK Inhibitor Therapy in Non–Small Cell Lung Cancer: A Pooled-Data Analysis on Diagnostic Operating Characteristics of Immunohistochemistry

Improving Selection Criteria for ALK Inhibitor Therapy in Non–Small Cell Lung Cancer: A Pooled-Data Analysis on Diagnostic Operating Characteristics of Immunohistochemistry

Jiang, Long MD, PhD; Yang, Haihong MD, PhD; He, Ping MD, PhD, et al.

This study evaluates the diagnostic role of ALK immunohistochemistry (IHC) in identification of ALK rearrangement compared to FISH. Authors conclude that IHC scores of 0 and 3+ were nearly 100% concordant with FISH-negative and FISH-positive status, respectively. However, IHC scores 1+ and 2+ might require further confirmatory testing by FISH assay. IHC assay using D5F3 and 5A4 antibodies reliably detected NSCLC with ALK rearrangement and may be useful as a screening method to identify these tumors.
Register now to review full resource. Or, if you have registered, login now.

FISH and molecular testing

+Template for reporting results of biomarker testing of specimens from patients with non-small cell carcinoma of the lung

Template for reporting results of biomarker testing of specimens from patients with non-small cell carcinoma of the lung

Cagle PT, et al.

Self-explanatory. A useful template for reporting biomarkers for lung cancer
Register now to review full resource. Or, if you have registered, login now.

+Template for Reporting Results of Biomarker Testing of Specimens From Patients With Non–Small Cell Carcinoma of the Lung

Template for Reporting Results of Biomarker Testing of Specimens From Patients With Non–Small Cell Carcinoma of the Lung

Philip T. Cagle, MD; Lynette M. Sholl, MD; Neal I. Lindeman, MD, et al.

The College of American Pathologists suggested templates when reporting results of biomarker testing to assist pathologists in providing clinically useful and relevant information
Register now to review full resource. Or, if you have registered, login now.

Other considerations

+Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model

Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model

Demicco EG, et al.

A risk assessment model for determining the likelihood for malignant behavior in solitary fibrous tumors, including those arising in the lung
Register now to review full resource. Or, if you have registered, login now.

+The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification

The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification

Travis WD, et al.

A nice and concise summary of the changes and additions made in the new 2015 WHO Classification of Lung Tumors
Register now to review full resource. Or, if you have registered, login now.

+Lung Carcinoma Staging Update

Lung Carcinoma Staging Update

Dacic, S

This short article is a brief review of the 8th edition staging system for lung cancer. The article primarily discusses the main changes to the T, N and M categories
Register now to review full resource. Or, if you have registered, login now.

+Challenges of Frozen Section in Thoracic Pathology: Lepidic Lesions, Limited Resections, and Margins

Challenges of Frozen Section in Thoracic Pathology: Lepidic Lesions, Limited Resections, and Margins

Borczuk AC.

This article discusses the pitfalls and challenges in frozen section evaluation. Common and rare scenarios are rerviewed.
Register now to review full resource. Or, if you have registered, login now.

+Evaluation of the 7th and 8th editions of the AJCC/UICC TNM staging systems for lung cancer in a large North American cohort. Oncotarget. 2017 May 24.

Evaluation of the 7th and 8th editions of the AJCC/UICC TNM staging systems for lung cancer in a large North American cohort. Oncotarget. 2017 May 24.

Yang L, Wang S, Zhou Y, et al.

The authors discuss modifications to the most recent staging system for lung cancer, highlighting improvements and contrasting with the prior staging system.
Register now to review full resource. Or, if you have registered, login now.

This website is sponsored by:

 Founding Sponsor

Copyright © 2017. The American Society for Clinical Pathology. All rights reserved.